{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:34:18Z","timestamp":1793522058582,"version":"4.5.0"},"reference-count":100,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>Following the clinical success of immune checkpoint antibodies targeting CTLA-4, PD-1 or PD-L1 in cancer treatment, bispecific antibodies are now emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. We describe three classes of immunotherapeutic bispecific antibodies: (a) cytotoxic effector cell redirectors; (b) tumor-targeted immunomodulators; and (c) dual immunomodulators. Cytotoxic effector cell redirectors are dominated by T-cell redirecting compounds, bispecific compounds engaging a tumor-associated antigen and the T-cell receptor\/CD3 complex, thereby redirecting T-cell cytotoxicity to malignant cells. This is the most established class of bispecific immunotherapies, with two compounds having reached the market and numerous compounds in clinical development. Tumor-targeted immunomodulators are bispecific compounds binding to a tumor-associated antigen and an immunomodulating receptor, such as CD40 or 4-1BB. Such compounds are usually designed to be inactive until binding the tumor antigen, thereby localizing immune stimulation to the tumor environment, while minimizing immune activation elsewhere. This is expected to induce powerful activation of tumor-specific T cells with reduced risk of immune-related adverse events. Finally, dual immunomodulators are bispecific compounds that bind two distinct immunomodulating targets, often combining targeting of PD-1 or PD-L1 with that of LAG-3 or TIM-3. The rationale is to induce superior tumor immunity compared to monospecific antibodies to the same targets. In this review, we describe each of these classes of bispecific antibodies, and present examples of compounds in development.<\/jats:p>","DOI":"10.1177\/2515135518763280","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T05:52:50Z","timestamp":1522216370000},"page":"3-17","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":202,"title":["Bispecific antibodies in cancer immunotherapy"],"prefix":"10.1177","volume":"6","author":[{"given":"Eva","family":"Dahl\u00e9n","sequence":"first","affiliation":[{"name":"Alligator Bioscience, 22381 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Veitonm\u00e4ki","sequence":"additional","affiliation":[{"name":"Alligator Bioscience, 22381 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Norl\u00e9n","sequence":"additional","affiliation":[{"name":"Alligator Bioscience, 22381 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"bibr1-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"bibr2-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"bibr3-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"bibr4-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30366-7"},{"key":"bibr5-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv623"},{"key":"bibr6-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"bibr7-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12459"},{"key":"bibr8-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1268307"},{"key":"bibr9-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1187802"},{"key":"bibr10-2515135518763280","unstructured":"AbbVie R&D Day. AbbVie 2016 R&D day presentation, http:\/\/investors.abbvie.com\/phoenix.zhtml?c=251551&p=irol-presentations (2016, accessed 3 June 2016)."},{"key":"bibr11-2515135518763280","doi-asserted-by":"crossref","unstructured":"Claus C, Ferrara C, Lang S, et al. A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells. In: The American association for cancer research annual meeting, AACR\u201917. Abstract 3634, Washington, DC, 1\u20135 April 2017. Philadelphia: AACR.","DOI":"10.1158\/1538-7445.AM2017-3634"},{"key":"bibr12-2515135518763280","volume-title":"The American association for cancer research annual meeting, AACR\u201916","author":"Hinner MJ"},{"key":"bibr13-2515135518763280","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-594","volume":"77","author":"Knudson KM","year":"2017","journal-title":"Cancer Res"},{"key":"bibr14-2515135518763280","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1158\/1538-7445.AM2016-3217","volume":"76","author":"LaMotte-Mohs R","year":"2016","journal-title":"Cancer Res"},{"key":"bibr15-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2769"},{"key":"bibr16-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318195b5bb"},{"key":"bibr17-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"bibr18-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"bibr19-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0945"},{"key":"bibr20-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"bibr21-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"bibr22-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"bibr23-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2909"},{"key":"bibr24-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-014-0029-x"},{"key":"bibr25-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"bibr26-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"bibr27-2515135518763280","first-page":"340","volume":"12","author":"Thakur A","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"bibr28-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0522-z"},{"key":"bibr29-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000976107"},{"key":"bibr30-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31819b7c70"},{"key":"bibr31-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3182307fd8"},{"key":"bibr32-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007"},{"key":"bibr33-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"bibr34-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"bibr35-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2764"},{"key":"bibr36-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3349"},{"key":"bibr37-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"bibr38-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.9970"},{"key":"bibr39-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2015.1041373"},{"key":"bibr40-2515135518763280","volume-title":"Prescribing information: Blincyto","author":"BLISCYTO\u00ae","year":"2017"},{"key":"bibr41-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00063"},{"key":"bibr42-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.2.11221"},{"key":"bibr43-2515135518763280","doi-asserted-by":"publisher","DOI":"10.7150\/jca.2.309"},{"key":"bibr44-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26258"},{"key":"bibr45-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00031"},{"key":"bibr46-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00122"},{"key":"bibr47-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00230"},{"key":"bibr48-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"bibr49-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2017.6"},{"key":"bibr50-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28591"},{"key":"bibr51-2515135518763280","volume-title":"EACR\u2013AACR\u2013SIC special conference 2017: the challenges of optimizing immuno- and targeted therapies \u2013 from cancer biology to the clinic, Brussels, Belgium","author":"Gantke T"},{"key":"bibr52-2515135518763280","volume-title":"EACR\u2013AACR\u2013SIC special conference 2017: the challenges of optimizing immuno- and targeted therapies \u2013 from cancer biology to the clinic, Brussels, Belgium","author":"Kluge M"},{"key":"bibr53-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzx043"},{"key":"bibr54-2515135518763280","unstructured":"GT Biopharma. Next generation TriKE OXS-C3350, tetra-specific natural killer cell engager (TetraKE) OXS-1615 and earlier stage product candidates. Washington, DC: GT Biopharma, Inc. 2018. www.gtbiopharma.com\/product-pipeline\/oxs-1615-and-oxs-c3550 (accessed 5 February 2018)."},{"key":"bibr55-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2017.07.011"},{"key":"bibr56-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2016.491"},{"key":"bibr57-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181d75c20"},{"key":"bibr58-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.243"},{"key":"bibr59-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1441-7"},{"key":"bibr60-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"bibr61-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0913"},{"key":"bibr62-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0067"},{"key":"bibr63-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27755"},{"key":"bibr64-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.698338"},{"key":"bibr65-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1303204"},{"key":"bibr66-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"bibr67-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.05.001"},{"key":"bibr68-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2010.88"},{"key":"bibr69-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2064"},{"key":"bibr70-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600146"},{"key":"bibr71-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv387"},{"key":"bibr72-2515135518763280","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008003"},{"key":"bibr73-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0152"},{"key":"bibr74-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.4882"},{"key":"bibr75-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.2739"},{"key":"bibr76-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.47"},{"key":"bibr77-2515135518763280","doi-asserted-by":"publisher","DOI":"10.4161\/onci.19974"},{"key":"bibr78-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61226"},{"key":"bibr79-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1733"},{"key":"bibr80-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"bibr81-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1243"},{"key":"bibr82-2515135518763280","unstructured":"PRS-343. Pieris Pharmaceuticals announces dosing of first patient in phase I trial for fully proprietary lead IO program. Boston, MA: Pieris Pharmaceuticals Inc. 2017. www.pieris.com\/news-and-events\/press-releases\/detail\/575\/pieris-pharmaceuticals-announces-dosing-of-first-patient-in (accessed 2 October 2017)."},{"key":"bibr83-2515135518763280","unstructured":"APV-527. Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG. Alligator Bioscience, 2017. https:\/\/alligatorbioscience.se\/en\/aptevo-therapeutics-and-alligator-bioscience-commence-ind-enabling-development-activities-for-new-bispecific-immunotherapy-candidate-alg-apv-527\/ (accessed 17 August 2017)."},{"key":"bibr84-2515135518763280","unstructured":"APV-527. Alligator Bioscience Aptevo Therapeutics: tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG. APV-527. Alligator Bioscience, Seattle, WA and Lund, Sweden, 2017. https:\/\/alligatorbioscience.se\/en\/alligator-bioscience-aptevo-therapeutics-tumor-antigen-5t4-associated-with-many-forms-of-solid-tumors-identified-as-the-second-target-for-alg-apv-527\/2017 (accessed 24 October 2017)."},{"key":"bibr85-2515135518763280","volume-title":"The American Association for Cancer Research annual meeting, AACR\u201917","author":"Liu L"},{"key":"bibr86-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e14626"},{"key":"bibr87-2515135518763280","volume-title":"proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival","author":"Hinner MJ"},{"key":"bibr88-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1267891"},{"key":"bibr89-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"bibr90-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501"},{"key":"bibr91-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"bibr92-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425"},{"key":"bibr93-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643"},{"key":"bibr94-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.112"},{"key":"bibr95-2515135518763280","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.11.001"},{"key":"bibr96-2515135518763280","doi-asserted-by":"crossref","first-page":"B091","DOI":"10.1158\/2326-6066.IMM2016-B091","volume":"4","author":"Doody J","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"bibr97-2515135518763280","unstructured":"Merus. Pipeline. Merus, 2017, Utrecht, The Netherlands, https:\/\/merus.nl\/pipeline\/ (accessed on 5 February 2018)."},{"key":"bibr98-2515135518763280","volume-title":"31st annual meeting of the Society for Immunotherapy of Cancer","author":"Hedvat M"},{"key":"bibr99-2515135518763280","volume-title":"SITC\u201917","author":"Veitonm\u00e4ki N"},{"key":"bibr100-2515135518763280","unstructured":"Alligator Bioscience. ATOR-1015. Alligator Bioscience, Lund, Sweden, 2017. https:\/\/alligatorbioscience.se\/en\/research-and-development\/pipeline\/ator-1015\/ (accessed 5 February 2018)."}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135518763280","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2515135518763280","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135518763280","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T17:13:39Z","timestamp":1740935619000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2515135518763280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1177\/2515135518763280"],"URL":"https:\/\/doi.org\/10.1177\/2515135518763280","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}